{
    "ticker": "INVO",
    "name": "Invo Bioscience, Inc.",
    "description": "Invo Bioscience, Inc. is an innovative biotechnology company focused on advancing reproductive health through its proprietary InvoCell technology. Founded in 2010, the company aims to provide accessible and effective solutions for couples facing infertility challenges. The InvoCell device allows for an in vivo culture of embryos, which significantly reduces the need for traditional in vitro fertilization (IVF) procedures. This breakthrough technology not only lowers costs associated with fertility treatments but also enhances the patient's overall experience by allowing the process to be completed in a more natural setting. Invo Bioscience is committed to expanding its presence in the global fertility market, which continues to grow due to increasing awareness and demand for fertility services. The company collaborates with healthcare providers and fertility clinics to improve patient outcomes and to ensure that its technology is easily integrated into existing treatment protocols. With a focus on research and development, Invo Bioscience is dedicated to delivering innovative solutions that empower individuals and couples on their journey to parenthood. The company\u2019s mission is to democratize access to fertility treatments and to make reproductive health care more affordable and accessible for all.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "North Attleboro, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.invobioscience.com",
    "ceo": "Steve Shum",
    "social_media": {
        "twitter": "https://twitter.com/invobioscience",
        "linkedin": "https://www.linkedin.com/company/invo-bioscience/"
    },
    "investor_relations": "https://www.invobioscience.com/investor-relations",
    "key_executives": [
        {
            "name": "Steve Shum",
            "position": "CEO"
        },
        {
            "name": "Misty H. M. Wyrick",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Fertility Solutions",
            "products": [
                "InvoCell"
            ]
        }
    ],
    "seo": {
        "meta_title": "Invo Bioscience, Inc. | Innovative Fertility Solutions",
        "meta_description": "Invo Bioscience, Inc. pioneers the InvoCell technology, providing accessible and effective fertility solutions for couples facing infertility challenges.",
        "keywords": [
            "Invo Bioscience",
            "Fertility",
            "InvoCell",
            "Biotechnology",
            "Reproductive Health"
        ]
    },
    "faq": [
        {
            "question": "What is Invo Bioscience known for?",
            "answer": "Invo Bioscience is known for its innovative InvoCell technology, which provides a more accessible and cost-effective fertility treatment option."
        },
        {
            "question": "Who is the CEO of Invo Bioscience?",
            "answer": "Steve Shum is the CEO of Invo Bioscience, Inc."
        },
        {
            "question": "Where is Invo Bioscience headquartered?",
            "answer": "Invo Bioscience is headquartered in North Attleboro, Massachusetts, USA."
        },
        {
            "question": "What is the main product of Invo Bioscience?",
            "answer": "The main product of Invo Bioscience is the InvoCell device, used for in vivo embryo culture."
        },
        {
            "question": "When was Invo Bioscience founded?",
            "answer": "Invo Bioscience was founded in 2010."
        }
    ],
    "competitors": [
        "IVF",
        "FERT",
        "CRAI"
    ],
    "related_stocks": [
        "AMGN",
        "GENE",
        "EXAS"
    ]
}